natgillin/translations-raw huggingface dataset:
Neupro 4 mg/24 h transdermal patch Each patch releases 4 mg of rotigotine per 24 hours. 
Neupro 4 mg/24 h transdermaalne plaaster Iga plaaster vabastab 24 tunni vältel 4 mg rotigotiini.
On the first day of treatment, start with Neupro 2 mg (package marked “Week 1”), and use one Neupro 2 mg transdermal patch daily. 
nädal”) ja kasutage iga päev ära üks Neupro 2 mg transdermaalne plaaster.
Neupro 4 mg/24 h transdermal patch The outside of the backing layer is tan-coloured and imprinted with ‘Neupro 4 mg/24 h'. 
Neupro 4 mg/24 h transdermaalne plaaster Pealiskihi välimine pool on beež ja sellel on jäljend ‘Neupro 4 mg/24 h'.
The outside of the backing layer is tan-coloured and imprinted with ‘Neupro 2 mg/24 h'. 
Pealiskihi välimine pool on beež ja sellel on jäljend ‘Neupro 2 mg/24 h'.
Disturbances in consciousness NEC 
Psühhiaatrilised häired tajumishäired a
Fall e a High Level Term b Observed in open-label studies c Observed during post-marketing d Observed in 2011 data pool of double-blind placebo-controlled studies e Observed in studies performed in patients with Parkinson's disease 
Täheldati turuletulekujärgsel perioodil d Topeltpimedate platseebokontrollitud kliiniliste uuringute ühendandmed (2011)
The outside is tan-coloured and is imprinted with Neupro 2 mg/24 h. 
Välimine pool on beež ja sellel on jäljend Neupro 2 mg/24 h.
Neupro 1 mg/24 h transdermal patch EU/1/05/331/038 
Neupro 1 mg/24 h transdermaalne plaaster EU/1/05/331/038
Dopamine dysregulation syndromec, perception disturbancese 
deliirium d dopamiini düsregulatsiooni sündroom c
Poly(dimethylsiloxane, trimethylsilyl silicate)-copolymerisate, Povidone K90, 
Polü(dimetüülsiloksaan, trimetüülsilüülsilikaat)-kopolümerisaat,
The outside is tan-coloured and is imprinted with Neupro 2 mg/24 h, 4 mg/24 h, 6 mg/24 h or 8 mg/24 h. 
Välimine pool on beež ja sellel on jäljend Neupro 2 mg/24 h, 4 mg/24 h, 6 mg/24 h või 8 mg/24 h.
Neupro 8 mg/24 h transdermal patch EU/1/05/331/010 
Neupro 8 mg/24 h transdermaalne plaaster EU/1/05/331/010
Neupro 6 mg/24 h transdermal patch EU/1/05/331/007 
Neupro 6 mg/24 h transdermaalne plaaster EU/1/05/331/007
Neupro 4 mg/24 h transdermal patch EU/1/05/331/004 
Neupro 4 mg/24 h transdermaalne plaaster EU/1/05/331/004
Neupro 3 mg/24 h transdermal patch EU/1/05/331/047 
Neupro 3 mg/24 h transdermaalne plaaster EU/1/05/331/047
EU/1/05/331/047 [7 transdermal patches] EU/1/05/331/049 [28 transdermal patches] EU/1/05/331/050 [30 transdermal patches] EU/1/05/331/058 [14 transdermal patches] 
EU/1/05/331/047 [7 transdermaalset plaastrit] EU/1/05/331/049 [28 transdermaalset plaastrit] EU/1/05/331/050 [30 transdermaalset plaastrit] EU/1/05/331/058 [14 transdermaalset plaastrit]
EU/1/05/331/038 [7 transdermal patches] EU/1/05/331/040 [28 transdermal patches] EU/1/05/331/041 [30 transdermal patches] EU/1/05/331/056 [14 transdermal patches] 
EU/1/05/331/038 [7 transdermaalset plaastrit] EU/1/05/331/040 [28 transdermaalset plaastrit] EU/1/05/331/041 [30 transdermaalset plaastrit] EU/1/05/331/056 [14 transdermaalset plaastrit]
Neupro 8 mg/24 h transdermal patch rotigotine 
Neupro 8 mg/24 h transdermaalne plaaster rotigotiin
EU/1/05/331/010 [7 transdermal patches] EU/1/05/331/011 [28 transdermal patches] EU/1/05/331/033 [30 transdermal patches] EU/1/05/331/061 [14 transdermal patches] 
EU/1/05/331/010 [7 transdermaalset plaastrit] EU/1/05/331/011 [28 transdermaalset plaastrit] EU/1/05/331/033 [30 transdermaalset plaastrit] EU/1/05/331/061 [14 transdermaalset plaastrit]
Neupro 2 mg/24 h transdermal patch 
Neupro 2 mg/24 h transdermaalne plaaster
Neupro 1 mg/24 h transdermal patch rotigotine 
Neupro 1 mg/24 h transdermaalne plaaster rotigotiin
The strengths are 1 mg/24 h, 2 mg/24 h and 3 mg/24 h for the treatment of Restless Leg Syndrome. 
Tugevused rahutute jalgade sündroomi raviks on 1 mg/24 h, 2 mg/24 h ja 3 mg/24 h.
EU/1/05/331/004 [7 transdermal patches] EU/1/05/331/005 [28 transdermal patches] EU/1/05/331/021 [30 transdermal patches] EU/1/05/331/059 [14 transdermal patches] 
EU/1/05/331/004 [7 transdermaalset plaastrit] EU/1/05/331/005 [28 transdermaalset plaastrit] EU/1/05/331/021 [30 transdermaalset plaastrit] EU/1/05/331/059 [14 transdermaalset plaastrit]
EU/1/05/331/001 [7 transdermal patches] EU/1/05/331/002 [28 transdermal patches] EU/1/05/331/015 [30 transdermal patches] EU/1/05/331/057 [14 transdermal patches] 
EU/1/05/331/001 [7 transdermaalset plaastrit] EU/1/05/331/002 [28 transdermaalset plaastrit] EU/1/05/331/015 [30 transdermaalset plaastrit] EU/1/05/331/057 [14 transdermaalset plaastrit]
EU/1/05/331/007 [7 transdermal patches] EU/1/05/331/008 [28 transdermal patches] EU/1/05/331/027 [30 transdermal patches] EU/1/05/331/060 [14 transdermal patches] 
EU/1/05/331/007 [7 transdermaalset plaastrit] EU/1/05/331/008 [28 transdermaalset plaastrit] EU/1/05/331/027 [30 transdermaalset plaastrit] EU/1/05/331/060 [14 transdermaalset plaastrit]
Neupro 6 mg/24 h transdermal patch rotigotine 
Neupro 6 mg/24 h transdermaalne plaaster rotigotiin
Vomiting, dyspepsia 
letargiae, krambide
AST, ALT, GGT), weight increased, heart rate increased, CPK increasedd 
ASAT, ALAT, GGT), kaalutõuse, kiirenenud pulss e, kreatiniinfosfokinaasi (CPK) taseme tõus d,e (vt
Component of a multipack, can't be sold separately 
42 transdermaalset plaastrit, hulgipakendi osa (ei müüda eraldi).
EU/1/05/331/053 [84 transdermal patches (3 packs of 28)] 
EU/1/05/331/053 [84 transdermaalset plaastrit (3 karpi á 28 plaastriga)]
EU/1/05/331/044 [84 transdermal patches (3 packs of 28)] 
EU/1/05/331/044 [84 transdermaalset plaastrit (3 karpi á 28 plaastriga)]
EU/1/05/331/036 [84 transdermal patches (3 packs of 28)] 
EU/1/05/331/036 [84 transdermaalset plaastrit (3 karpi á 28 plaastriga)]
EU/1/05/331/018 [84 transdermal patches (3 packs of 28)] 
EU/1/05/331/018 [84 transdermaalset plaastrit (3 karpi á 28 plaastriga)]
EU/1/05/331/024 [84 transdermal patches (3 packs of 28)] 
EU/1/05/331/024 [84 transdermaalset plaastrit (3 karpi á 28 plaastriga)]
syncope, syncope vasovagal, loss of consciousness), dyskinesiae, dizziness posturale, lethargye, convulsion e 
(k.a sünkoop, vasovagaalne sünkoop, teadvusekaotus), düskineesia, posturaalne pearinglus, letargia krambid langetatud pea sündroom c,e
Application and instillation site reactionsa (incl. 
Üldised häired ja manustamiskoha reaktsioo-* nid reaktsioonid kasutamis- ja manustamiskohal a
Neupro 4 mg/24 h transdermal patch Rotigotine 
Neupro 4 mg/24 h transdermaalne plaaster rotigotiin
Oedema peripheral, asthenic conditionsa (incl. 
perifeerne turse, asteenilised seisundid a
Neupro 3 mg/24 h transdermal patch rotigotine 
Neupro 3 mg/24 h transdermaalne plaaster rotigotiin
Neupro 2 mg/24 h transdermal patch Rotigotine 
Neupro 2 mg/24 h transdermaalne plaaster rotigotiin
EU/1/05/331/030 [84 transdermal patches (3 packs of 28)] 
EU/1/05/331/030 [84 transdermaalset plaastrit (3 karpi á 28 plaastriga)]
syncope, syncope vasovagal, loss of consciousness), dyskinesiae, dizziness posturale, lethargye, convulsione 
(k.a sünkoop, vasovagaalne sünkoop, teadvusekaotus), düskineesia, posturaalne pearinglus, letargia krambid langetatud pea sündroom c
• itching 
• pearinglus
syncope, syncope vasovagal, loss of consciousness), dyskinesia, dizziness postural, lethargy 
(k.a sünkoop, vasovagaalne sünkoop, teadvusekaotus), düskineesia e,
Ref.: EMEA/356088/2009 EMEA/H/C/1053 
Viide: EMEA/484207/2009 EMEA/H/C/1053
It is available as pink tablets (75 mg). 
Seda turustatakse roosade tablettidena (75 mg).
The standard dose of Clopidogrel Teva is one 75 mg tablet once a day, taken with or without food. 
Clopidogrel Teva tavaannus on üks 75 mg tablett üks kord ööpäevas koos toiduga või ilma.
In acute coronary syndrome, Clopidogrel Teva is used together with aspirin and treatment generally starts with a loading dose of four 75 mg tablets. 
Akuutse koronaarsündroomi korral kasutatakse Clopidogrel Tevat koos aspiriiniga; ravi algab üldiselt küllastusannusega, kus võetakse neli 75 mg tabletti.
Clopidogrel Teva can be started between seven days and six months after the stroke; 
Clopidogrel Teva manustamist võib alustada seitsme päeva kuni kuue kuu jooksul pärast insulti;
Clopidogrel Teva can be given to the following groups of patients: 
Clopidogrel Tevat võib kasutada järgmiste patsiendirühmade korral:
The Committee recommended that Clopidogrel Teva be given marketing authorisation. 
Komitee soovitas anda Clopidogrel Tevale müügiloa.
Clopidogrel Teva clopidogrel EPAR summary for the public 
Clopidogrel Teva klopidogreel Kokkuvõte üldsusele
The European Commission granted a marketing authorisation valid throughout the EU for Clopidogrel Teva to Teva Pharma B.V. on 28 July 2009. 
Euroopa Komisjon andis Clopidogrel Teva müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, ettevõttele Teva Pharma B.V.28.
The full EPAR for Clopidogrel Teva can be found here. 
Euroopa avaliku hindamisaruande täisteksti Clopidogrel Teva kohta leiate siit.
Clopidogrel Teva is a ‘generic medicine'. 
Clopidogrel Teva on geneeriline ravim.
Because Clopidogrel Teva is a generic medicine and is bioequivalent to the reference medicine, its benefit and risk are taken as being the same as those of the reference medicine. 
Et Clopidogrel Teva on geneeriline ravim ja võrdlusravimiga bioekvivalentne, peetakse tema kasulikkust ja riske samadeks mis võrdlusravimil.
This means that Clopidogrel Teva is similar to a ‘reference medicine' already authorised in the European Union (EU) called Plavix. 
See tähendab, et Clopidogrel Teva on sarnane võrdlusravimiga Plavix, millel juba on Euroopa Liidus müügiluba.
Clopidogrel Teva can be started between a few days and 35 days after the attack; 
Clopidogrel Teva manustamist võib alustada mõne kuni 35 päeva jooksul pärast infarkti;
The Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Clopidogrel Teva has been shown to have comparable quality and to be bioequivalent to Plavix. 
Inimravimite komitee otsustas, et vastavalt Euroopa Liidu nõuetele on tõendatud Clopidogrel Teva võrdväärne kvaliteet ja bioekvivalentsus ravimiga Plavix.
Clopidogrel Teva can be used in patients who are having myocardial infarction with ‘ST segment elevation' (an abnormal reading on the ECG or electrocardiogram) when the doctor thinks that they would benefit from the treatment. 
Clopidogrel Tevat võib manustada ka patsientidele, kellel on ST-segmendi elevatsiooniga (elektrokardiogrammi ehk EKG teatud ebanormaalne näit) südameinfarkt, kui arst arvab, et ravimist on patsiendile kasu.
Clopidogrel Teva is a medicine that contains the active substance clopidogrel. 
Clopidogrel Teva on ravim, mis sisaldab toimeainena klopidogreeli.
Other information about Clopidogrel Teva: 
Muu teave Clopidogrel Teva kohta
Therefore, the CHMP's view was that, as for Plavix, the benefit outweighs the identified risk. 
Seetõttu arvas inimravimite komitee, et nagu ka Plavixi puhul, ületab Clopidogrel Teva kasulikkus sellega kaasnevad riskid.
Doc. 
juulil 2009.
It can also be used in patients who do not have this abnormal reading on the ECG, if they have unstable angina (a severe type of chest pain) or ‘non-Q-wave' myocardial infarction. 
Samuti võib Clopidogrel Tevat kasutada patsientidel, kellel seda ebanormaalset EKG-näitu ei ole, kui neil on ebastabiilne rinnaangiin (tugevad valud rindkeres) või on Q-sakita südameinfarkt.
Because Clopidogrel Teva is a generic medicine, studies have been limited to tests to determine that it is bioequivalent to the reference medicine, Plavix. 
Et Clopidogrel Teva on geneeriline ravim, piirdusid uuringud katsetega, milles näidati Clopidogrel Teva bioekvivalentsust võrdlusravimiga Plavix.
Clopidogrel Teva is used in adults to prevent atherothrombotic events (problems caused by blood clots and hardening of the arteries). 
Clopidogrel Tevat kasutatakse aterotrombootiliste nähtude (trombide ehk soonesiseste verehüüvete moodustumisest ja arterite lubjastumisest põhjustatud probleemide) ennetamiseks täiskasvanutel.
Why has Clopidogrel Teva been approved? 
Miks Clopidogrel Teva heaks kiideti?
What are the benefit and risk of Clopidogrel Teva? 
Milles seisneb Clopidogrel Teva kasulikkus ja mis riskid ravimiga kaasnevad?
How has Clopidogrel Teva been studied? 
Kuidas Clopidogrel Tevat uuriti?
• patients who have a condition known as ‘acute coronary syndrome', when it should be given with aspirin (another medicine that prevents blood clots), including patients who have had a stent inserted (a short tube placed in an artery to prevent it closing up). 
Sel juhul tuleb Clopidogrel Tevat manustada koos aspiriiniga (samuti antikoagulant), sealhulgas patsientidele, kellele on paigaldatud stent (ahenenud arterit avardav väike toru).
What is Clopidogrel Teva used for? 
Milleks Clopidogrel Tevat kasutatakse?
How is Clopidogrel Teva used? 
Kuidas Clopidogrel Tevat kasutatakse?
The active substance in Clopidogrel Teva, clopidogrel, is an inhibitor of platelet aggregation. 
Clopidogrel Teva toimeaine klopidogreel on trombotsüütide agregatsiooni (vereliistakute kokkukleepumise) inhibiitor, mis aitab ennetada trombide (soonesiseste verehüüvete) teket.
How does Clopidogrel Teva work? 
Kuidas Clopidogrel Teva toimib?
Neutropenia lasted on average 1.6 days with both medicines. 
Mõlema ravimiga kestis neutropeenia keskmiselt 1,6 päeva.
Further information on Pelgraz can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Lisateave Pelgrazi kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
What measures are being taken to ensure the safe and effective use of Pelgraz? 
Mis meetmed võetakse, et tagada Pelgrazi ohutu ja efektiivne kasutamine?
Pelgraz (pegfilgrastim) 
Pelgraz (pegfilgrastiim)
This means that Pelgraz is highly similar to another biological medicine (the ‘reference medicine') that is already authorised in the EU. 
See tähendab, et Pelgraz on väga sarnane teise bioloogilise ravimiga (võrdlusravimiga), millel juba on ELis müügiluba.
What is Pelgraz and what is it used for? 
Mis on Pelgraz ja milleks seda kasutatakse?
As for all medicines, data on the use of Pelgraz are continuously monitored. 
Nagu kõigi ravimite puhul, teostatakse Pelgrazi kasutamise kohta pidevat järelevalvet.
Other information about Pelgraz 
Muu teave Pelgrazi kohta
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Pelgraz have been included in the summary of product characteristics and the package leaflet. 
Pelgrazi ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
For more information about using Pelgraz, see the package leaflet or contact your doctor or pharmacist. 
Lisateavet Pelgrazi kasutamise kohta vt pakendi infolehest või konsulteeri oma arsti või apteekriga.
The European Medicines Agency decided that, in accordance with EU requirements for biosimilar medicines, Pelgraz has a highly similar structure, purity and biological activity to Neulasta and is distributed in the body in the same way. 
Euroopa Ravimiamet otsustas, et vastavalt ELi nõuetele bioloogiliselt sarnaste ravimite kohta sarnaneb Pelgraz struktuuri, puhtuse ja bioloogilise toime poolest Neulastaga ning et Pelgraz jaotub organismis samamoodi.
The active substance in Pelgraz, pegfilgrastim, consists of filgrastim, which is very similar to a human protein called granulocyte-colony-stimulating factor (G-CSF). 
Pelgrazi toimeaine pegfilgrastiim sisaldab filgrastiimi, mis on väga sarnane inimvalguga, mida nimetatakse granulotsüütide kolooniaid stimuleerivaks faktoriks (G-CSF).
Therefore, the Agency's view was that, as for Neulasta, the benefit of Pelgraz outweighs the identified risk and it can be authorised for use in the EU. 
Seetõttu on amet arvamusel, et nagu ka Neulasta korral, ületab Pelgrazi kasulikkus sellega kaasnevad riskid ja et ravimi kasutamise võib ELis heaks kiite.
Because Pelgraz is a biosimilar medicine, the studies on effectiveness and safety of pegfilgrastim carried out with Neulasta do not all need to be repeated for Pelgraz. 
Et Pelgraz on bioloogiliselt sarnane ravim, ei pea Neulastaga tehtud pegfilgrastiimi efektiivsus- ja ohutusuuringuid Pelgraziga kordama.
Side effects reported with Pelgraz are carefully evaluated and any necessary action taken to protect patients. 
Pelgrazi kõrvaltoimeid hinnatakse hoolikalt ja patsientide kaitseks rakendatakse vajalikke meetmeid.
The most common side effect with Pelgraz (which may affect more than 1 in 10 people) is pain in the bones. 
Pelgrazi kõige sagedam kõrvalnäht (võib esineda enam kui 1 patsiendil 10st) on luuvalu.
The reference medicine for Pelgraz is Neulasta. 
Pelgrazi võrdlusravim on Neulasta.
Pelgraz is given as a single dose of 6 mg injected under the skin at least 24 hours after the end of each cycle of chemotherapy (treatment with cancer medicines). 
Pelgrazi manustatakse annuses 6 mg ühekordse nahaaluse süstena vähemalt 24 tundi pärast iga keemiaravitsükli (vähi ravimravi) lõppu.
What are the risks associated with Pelgraz? 
Mis riskid Pelgraziga kaasnevad?
How does Pelgraz work? 
Kuidas Pelgraz toimib?
For the full list of side effects and restrictions with Pelgraz, see the package leaflet. 
Pelgrazi kohta teatatud kõrvalnähtude ja piirangute täielik loetelu on pakendi infolehel.
Pelgraz is not intended for use in patients with the blood cancer chronic myeloid leukaemia or with myelodysplastic syndromes (conditions in which large numbers of abnormal blood cells are produced, , which can develop into leukaemia). 
Pelgraz ei ole ette nähtud kasutamiseks kroonilise müeloidleukeemia (teatud verevähi) või müelodüsplastiliste sündroomidega (haigusseisundid, mille korral patsiendi organismis tekib suurel hulgal ebanormaalseid vererakke, mille tagajärjel võib välja kujuneda leukeemia) patsientidel.
Studies have also shown that giving Pelgraz produces similar levels of the active substance in the body to giving Neulasta. 
Uuringud on samuti tõendanud, et Pelgraz tekitab organismis sarnase toimeainesisalduse kui Neulasta.
An overview of Pelgraz and why it is authorised in the EU 
Ülevaade ravimist Pelgraz ja ELis müügiloa väljastamise põhjendus
All these data were considered sufficient to conclude that Pelgraz will behave in the same way as Neulasta in terms of effectiveness and safety in its approved uses. 
Nende piisavate andmete põhjal järeldati, et Pelgrazi efektiivsus ja ohutus on heakskiidetud näidustustel võrreldav Neulasta efektiivsuse ja ohutusega.
In addition, a study in breast cancer patients undergoing chemotherapy has shown that the effectiveness of Pelgraz is equivalent to that of Neulasta in reducing the duration of neutropenia. 
Peale selle tõendati keemiaravi läbinud rinnavähipatsientide uuringus, et Pelgraz oli neutropeenia kestuse vähendamisel sama efektiivne kui Neulasta.
Pelgraz is a ‘biosimilar medicine'. 
Pelgraz on bioloogiliselt sarnane ravim.
Pelgraz can only be obtained with a prescription and treatment should be started and supervised by a doctor who has experience in the treatment of cancer or blood disorders. 
Ravi peab algama ja toimuma vähi või verehäirete ravis kogenud arsti järelevalve all.
How is Pelgraz used? 
Kuidas Pelgrazi kasutatakse?
In Pelgraz, filgrastim has been ‘pegylated' (attached to a chemical called polyethylene glycol). 
Pelgrazis on filgrastiim pegüleeritud (kinnitatud keemilise aine polüetüleenglükooli külge).
Laboratory studies comparing Pelgraz with Neulasta have shown that the active substance in Pelgraz is highly similar to that in Neulasta in terms of structure, purity and biological activity. 
Pelgrazi võrreldi Neulastaga laboriuuringutes, mis tõendasid, et Pelgrazi toimeaine on struktuuri, puhtuse ja bioloogilise toime poolest väga sarnane Neulasta toimeainega.
What benefits of Pelgraz have been shown in studies? 
Milles seisneb uuringute põhjal Pelgrazi kasulikkus?
In addition, a study involving 589 patients who had chemotherapy after surgery for breast cancer showed that Pelgraz was as effective as Neulasta in reducing the duration of neutropenia. 
Lisaks oli Pelgraz neutropeenia kestuse vähendamisel sama efektiivne kui Neulasta uuringus, milles osales 589 patsienti, kes said pärast rinnavähi operatsiooni keemiaravi.
Pelgraz is a medicine used in cancer patients to help with neutropenia (low levels of neutrophils, a type of white blood cell), which is a common side effect of cancer treatment and can leave patients vulnerable to infections. 
Pelgraz on ravim, mida kasutatakse vähipatsientidel neutropeenia (neutrofiilide ehk teatud valgevereliblede vähesuse) leevendamiseks.
This summary was last updated on 11.01.2007. 
Kokkuvõtte viimane uuendus: 11.01.2007.
Its effect can be seen within about 2 weeks, and lasts for 5 months. 
Selle toime ilmneb ligikaudu 2 nädala jooksul ja püsib 5 kuud.
Wash hands after administration. 
Pärast manustamist peske käed.
The European Commission granted a marketing authorisation valid throughout the European Union, for Ypozane to Virbac S.A. on 11.01.2007. 
Euroopa Komisjon väljastas Ypozane müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, ettevõttele Virbac S.A. 11.01.2007.
The medicine is available as 1.875 mg, 3.75 mg, 7.5 mg or 15 mg tablets, which can be used for dogs of different weights (small, medium sized, large or very large dogs). 
Ravim on saadaval 1,875 mg, 3,75 mg, 7,5 mg või 15 mg tablettidena, mida võib kasutada eri kehamassiga koertel (väikesed, keskmised, suured või väga suured koerad).
After this time, the dog should be re-examined by a veterinarian and treatment might be repeated. 
Pärast selle aja möödumist peab veterinaararst koera uuesti läbi vaatama ja ravi võib korrata.
A clinical response to treatment (reduction of prostate volume) was seen within 14 days, which lasted for at least 5 months. 
Kliiniline ravivastus (eesnäärme vähenemine) ilmnes 14 päeva jooksul ja püsis vähemalt 5 kuud.
Ypozane is given daily for 7 days. 
Ypozanet antakse üks kord päevas 7 päeva jooksul.
This veterinary medicine has been developed especially for dogs and is not for use in humans. 
See veterinaarravim on välja töötatud spetsiaalselt koertele ja see ei ole ette nähtud inimestel kasutamiseks.
The most common side effects are a transient increase in appetite, and changes in the behaviour of the dog (changes in activity levels, more sociable behaviour). 
Kõige sagedamad kõrvaltoimed on mööduv söögiisu suurenemine ja muutused koera käitumises (muutub aktiivsuse tase, seltsivam käitumine).
The effectiveness of osaterone acetate was investigated in a large study undertaken in a number of veterinary practices across Europe. 
Osateroonatsetaadi efektiivsust uuriti suures uuringus, mida viidi läbi Euroopa mitmes veterinaariakliinikus.
Information on the prescription status of this product may be found on the label/outer package. 
Teave selle ravimi retseptinõuete kohta on esitatud etiketil/välispakendil.
Ypozane has no adverse effects on semen quality. 
Ypozane ei kahjusta sperma kvaliteeti.
The dogs received once a day for 7 days, one Ypozane tablet appropriate for their size to correspond to a daily dose of 0.250.5 mg osaterone acetate per kilogram bodyweight. 
Koertele anti 7 päeva jooksul üks kord päevas üks Ypozane tablett, nii et vastavalt koera suurusele oli päevaannuseks 0,25-0,5 mg osateroonatsetaati kehamassi kilogrammi kohta.
This is when male dogs suddenly become attractive to other male dogs or the size of their mammary glands increases. 
Selle puhul muutuvad isased koerad äkki atraktiivseks teistele isastele koertele või nende piimanäärmed suurenevad.
If a person accidentally takes the medicine, seek medical advice immediately and show the package leaflet or the label to a doctor. 
Juhusliku allaneelamise korral pöörduge kohe arsti poole ja näidake ravimi pakendi infolehte või etiketti.
Some dogs might also show vomiting, diarrhoea or increased thirst, or might develop a “feminisation syndrome”. 
Mõnel koeral võib esineda ka oksendamine, kõhulahtisus või janu suurenemine või feminisatsiooni sündroom.